Health & Environmental Research Online (HERO)


Print Feedback Export to File
1407596 
Journal Article 
Review 
Olanzapine: review of safety 2008 
Kantrowitz, JT; Citrome, L 
2008 
Yes 
Expert Opinion on Drug Safety
ISSN: 1474-0338 
7 
6 
761-769 
English 
18983222 
BACKGROUND: Olanzapine is a second-generation antipsychotic approved for the treatment of schizophrenia, bipolar mania and associated agitation.

OBJECTIVE: To assess the safety profile of olanzapine, including its propensity to be associated with weight gain, diabetes mellitus and dyslipidemias.

METHODS: Review of English-language reports located through PubMed and information available on regulatory agency websites.

RESULTS/CONCLUSION: The use of olanzapine can pose a therapeutic dilemma in that on one hand, a number of large scale studies have found effectiveness advantages for olanzapine in comparison to other first-line second-generation medications. On the other hand, olanzapine is associated with substantial weight gain and the development of dyslipidemia. Regarding other important safety concerns, olanzapine has a favorable profile in terms of extra-pyramidal side effects and is also relatively prolactin-sparing. The effectiveness benefits may outweigh the risks, particularly in patients with low baseline risk for metabolic syndrome but monitoring for untoward metabolic effects crucial. Switch-or-stay and other intervention decisions need to be made early before substantial weight gain has occurred.